AOTI Inc. CEO Dr. Mike Griffiths joined Steve Darling from Proactive to announce a key milestone in the company’s commercial expansion strategy: the successful approval of a new Provider ID in California. This designation allows AOTI to begin securing insurance coverage and reimbursement for its patented TWO2® Topical Wound Oxygen therapy in the country’s most populous Medicaid market, paving the way for broader growth in late 2026.
California represents a major strategic opportunity, with 14.7 million individuals—or 38% of the population—covered under Medi-Cal, the state’s Medicaid program. The addition of California marks the third state in 2025 where AOTI has secured provider status, aligning with the company’s guidance of adding two to three states annually as part of its U.S. expansion.
Griffiths emphasized that the TWO2® therapy, which is non-invasive and self-administered at home, has been clinically proven to significantly reduce the recurrence of Diabetic Foot Ulcers. Robust randomized controlled trials and real-world evidence have shown an 88% reduction in hospitalizations and a 71% reduction in amputations over 12 months—outcomes that not only improve quality of life but reduce healthcare system burden.
Financially, AOTI reported 26% revenue growth in the first three months of the period and 37% growth for the six months ended March 31, 2025—driven by strong post-IPO momentum.
Despite these short-term headwinds, AOTI remains confident in its long-term growth trajectory, forecasting mid-teens revenue growth and low double-digit adjusted EBITDA margins for FY 2025. The company views current macroeconomic challenges as transitional and reaffirmed its commitment to executing its strategic plan and expanding market access for its differentiated wound care technology.
#proactiveinvestors #aotiinc #aim #aoti #DiabeticFootUlcers #WoundCare #OxygenTherapy #HealthcareInnovation #Medicaid #VeteransHealth #CaliforniaHealthcare #ProactiveInvestors
